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Abstract
Thirty different genes including cytokines, chemokines, granzymes, perforin and specifically
integrins were evaluated in Peyer's patch-KdGag197–205-specific CD8+ T cells (pools of 100
cells) using Fluidigm 48.48 Dynamic arrays following three different prime-boost immunization
strategies. Data revealed that the route of prime or the booster immunization differentially influ-
enced the integrin expression profile on gut KdGag197–205-specific CD8+ T cells. Specifically, el-
evated numbers of integrin αE and αD expressing gut KdGag197–205-specific CD8+ T cells were
detected followingmucosal but not systemic priming. Also, αE/β7 and αD/β2 heterodimerization
were more noticeable in an intranasal (i.n.)/i.n. vaccination setting compared to i.n./intramuscu-
lar (i.m) or i.m./i.m. vaccinations. Moreover, in all vaccine groups tested α4 appeared to hetero-
dimerize more closely with β7 then β1. Also MIP-1β, RANTES, CCR5, perforin and integrin α4
bio-markers were significantly elevated in i.n./i.m. and i.m./i.m. immunization groups compared
to purely mucosal i.n./i.n. delivery. Furthermore, when wild type (WT) BALB/c and IL-13 knock-
out (KO) mice were immunized using i.n./i.m. strategy, MIP-1α, MIP-1β, RANTES, integrins α4,
β1 and β7mRNA expression levels were found to be significantly different, in mucosal verses
systemic KdGag197–205-specific CD8+ T cells. Interestingly, the numbers of gut KdGag197–205-
specific CD8+ T cells expressing gut-homingmarkers α4β7 and CCR9 protein were also signifi-
cantly elevated in IL-13 KO compared toWT control. Collectively, our findings further corrobo-
rate that the route of vaccine delivery, tissuemicroenvironment and IL-13 depleted cytokine
milieu can significantly alter the antigen-specific CD8+ T cell gene expression profiles and in
turn modulate their functional avidities as well as homing capabilities.
Introduction
It is now well established that route of vaccine delivery can greatly influence the quality of
HIV-specific CD8+ T cell immunity. Purely systemic immunization strategies intramuscular
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(i.m.) or intravenous (i.v.) immunizations) generate mainly long-lasting systemic immunity,
whereas mucosal immunization (i.n, intrarectal (i.r.) or oral) is able to induce “long lasting”
mucosal immune responses at the local and distant mucosa [1–4]. It has been shown that ma-
caques vaccinated with i.m. DNA-HIV vaccine priming followed by i.n. or i.r. fowlpox virus
(FPV)-HIV booster immunization generated enhanced local T-cell immunity in cervico-
vaginal tissues, and they were protected against a mucosal SHIV challenge [5]. Studies where
i.m. pDNA-HIV/ i.n FPV-HIV; i.n. FPV-HIV/ i.m. attenuated vaccinia virus (VV)-HIV and
i.n. VV-HIV/ i.m. FPV-HIV were evaluated, i.n. FPV-HIV prime followed by i.m. VV-HIV
booster vaccination has shown to induce robust polyfunctional HIV-specific T cell immunity
compared to the two other prime-boost vaccination strategies [6]. Notably, control of HIV rep-
lication in elite controllers (< 1%) have been associated with enhanced high avidity polyfunc-
tional HIV-specific CD8+ T cells [7, 8]. Our studies also clearly demonstrated that rFPV was
an excellent mucosal delivery vector. We have also shown that compared to purely systemic
(i.m FPV-HIV/ i.m VV-HIV) immunization regime, i.n. FPV-HIV prime followed by i.m
VV-HIV booster immunization strategy induce robust long lasting CD8+ systemic and muco-
sal T cell responses to HIV-1 vaccine antigens [9], which were also of higher avidity [10, 11].
Furthermore, purely mucosal immunization i.n./i.n. or combined mucosal systemic i.n./i.m im-
munization induced HIV-specific CD8+ T cells with lower IL-4 and IL-13 expression com-
pared to systemic immunization (i.m./i.m.), which were of higher avidity. Later studies using
IL-13 KO mice have confirmed that IL-13 can significantly dampen the induction of effector
and memory CD8+ T cells of higher avidity following vaccination [10, 12].
Studies have also shown that tissue microenvironment (i.e. mucosal vs. systemic compart-
ments) influence the nature of immune responses induced at mucosal and systemic sites [13–
15]. Unlike systemic compartment, due to the ability of antigens to be processed and presented
via the microfold or M cells, immune responses induced in the mucosal compartment is unique-
ly different [16, 17]. It is known that, locally activated mucosal DCs but not splenic-DCs have
the ability to imprint T cells with mucosal homing markers [18, 19]. For example, DCs purified
from Peyer’s patches and mesenteric lymph nodes (MLNs) but not from spleen or peripheral
lymph nodes induce T cell expression of both α4β7 and CCR9 in vitro and licence effector/mem-
ory T cells to home preferentially to intestinal epithelium [18, 19]. Notably, only gut-DCs (but
not DCs from other lymphoid organs) can produce retinoic acid from retinol (vitamin A), and
it has been shown that retinoic acid plays a critical role in imprinting of gut-homing specificities
on T cells [20]. These studies highlights the importance of mucosal vaccination in the process of
inducing long-lived mucosal-specific T cell immunity. Unfortunately, no clear biomarkers are
currently available to measure HIV-specific mucosal vaccine-specific CD8+ T cell immunity,
during human or NHP HIV vaccine trials, obtaining enough HIV-specific CD8 T cells from gut
or rectal biopsies to evaluate mucosal immunity can be a difficult task. Specifically, due to small
sample size obtaining meaningful data from FACS ELISPOT, can be a difficult task [21]. Thus,
finding new biomarkers that can be used to evaluate mucosal immunity, under these circum-
stances can to be of great importance, and this forms the basis of this project.
Therefore, in this study, with the hope of identifying gene expression profiles unique to mu-
cosal and systemic vaccination, thirty genes comprised of cytokines, chemokines, granzymes,
perforin, markers which are involved in immune regulation and integrins (Table 1), were eval-
uated using Fluidigm 48.48 Dynamic array system. Specifically the array of integrins were se-
lected as i) some of these molecules have shown to provoke lymphocyte homing to specific
tissues, and ii) enhanced expression of certain homing receptors on antigen-specific T cells fol-
lowing mucosal vaccination has been associated with mucosal T cell homing and control of
viral replication at the mucosae [22–24]. In this study mRNA expression profiles were evaluat-
ed in pools of hundred gut KdGag197–205-specific (tetramer-specific) CD8
+ T cells obtained
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from i.n./i.n. (purely mucosal), i.n./i.m. (mucosal/systemic) and i.m./i.m. (purely systemic)
FPV-HIV/VV-HIV prime-boost vaccinated BALB/c mice and hundred gut and splenic
KdGag197–205-specific CD8
+ T cells obtained from BALB/c and IL-13 KO animals following
i.n./i.m. immunization. In our previous studies mucosal immunization [10], and IL-13 depleted
cell milieu has shown to promote the induction of higher avidity HIV-specific CD8+ T cells,
where avidity profile of IL-13 KO>WT BALB/C mice [12].
Results
Mucosal and systemic vaccination can induce distinct mRNA expression
profiles in gut-KdGag197–205-specific CD8
+ T cells
WT BALB/c (n = 4–5) were primed with FPV-HIV and boosted with VV-HIV vaccine using
i.n./i.n., i.n./i.m. or i.m./i.m. vaccine regimes as indicated in methods, fourteen days post booster
Table 1. Genes of interest used in this study for mRNA quantification using Fluidigm 48.48 dynamic array nanofluidic chip.
N Gene symbol Gene name Category Reference sequence Assay ID
1 RpL32 Ribosomal protein L32 Endogenous standards NM_172086.2 Mm02528467_g1
2 IFN-γ Interferon gamma Cytokines NM_008337.3 Mm01168134_m1*
3 IL-2 Interleukin 2 Cytokines NM_008366.2 Mm00434256_m1*
4 TNF-α Tumor necrosis factor alpha Cytokines NM_013693.2 Mm00443258_m1*
5 IL-4 Interleukin-4 Cytokines NM_021283.2 Mm00445259_m1*
6 IL-13 Interleukin-13 Cytokines NM_008355.3 Mm00434204_m1*
7 IL-17 Interleukin-17 Cytokines NM_010552.3 Mm00439618_m1*
8 MIP-1α (CCL3) chemokine (C-C motif) ligand 3 Chemokines NM_011337.2 Mm00441258_m1*
9 MIP-1β (CCL4) chemokine (C-C motif) ligand 4 Chemokines NM_013652.2 Mm00443111_m1*
10 RANTES (CCL5) chemokine (C-C motif) ligand 5 Chemokines NM_013653.3 Mm01302428_m1*
11 Gzm A Granzyme A Protease NM_010370.2 Mm00439191_m1*
12 Gzm B Granzyme B Protease NM_013542.2 Mm00442834_m1*
13 Gzm C Granzyme C Protease NM_010371.2 Mm01313651_m1*
14 Prf1 Perforin 1 Defense protein NM_011073.3 Mm00812512_m1*
15 Sell (CD62L) L-selectin Cell adhesion molecule NM_011346.1 Mm00441291_m1*
16 Selplg (Psgl1) P-selectin ligand Receptor NM_009151.3 Mm01204601_m1*
17 CD69 CD69 antigen Receptor NM_001033122.3 Mm01183378_m1*
18 CCR5 Chemokine (C-C motif) receptor 5 Receptor NM_009917.5 Mm01216171_m1*
19 CCR7 Chemokine (C-C motif) receptor 7 Receptor NM_007719.2 Mm01301785_m1*
20 CCR9 Chemokine (C-C motif) receptor 9 Receptor NM_009913.5 Mm02620030_s1*
21 CCR10 Chemokine (C-C motif) receptor 10 Receptor NM_007721.4 Mm01292449_m1*
22 Itgα4 Integrin alpha 4 Integrin NM_010576.3 Mm00439770_m1*
23 ItgαE Integrin alpha E Integrin 2 Refseqs Mm00434443_m1*
24 ItgαL Integrin alpha L Integrin 4 Refseqs Mm00801807_m1*
25 ItgαM (CD11b) Integrin alpha M Integrin 2 Refseqs Mm00434455_m1*
26 ItgαX (CD11c) Integrin alpha X Integrin NM_021334.2 Mm00498698_m1*
27 ItgαD (CD11d) Integrin alpha D Integrin NM_001029872.2 Mm01159115_m1*
28 Itgβ1 Integrin beta 1 (ﬁbronectin receptor beta) Integrin NM_010578.2 Mm01253228_g1*
29 Itgβ2 Integrin beta 2 Integrin NM_008404.4 Mm00434513_m1*
30 Itgβ7 Integrin beta 7 Integrin NM_013566.2 Mm00442916_m1*
Note: In assay ID column * indicates the relevant accession numbers of the TaqMan primer probe sets used in the study obtained from Applied
Biosystems (Life Technologies, USA).
doi:10.1371/journal.pone.0126487.t001
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immunization gut KdGag197–205-specific CD8
+ T cell were sorted in groups of hundred cells
and mRNA expression profiles of 30 genes of interest (Table 1) were evaluated using Fluidigm
48.48 Dynamic arrays. When expression of cytokines IFN-γ, TNF-α, IL-2, IL-4, IL-13 and IL-17
mRNA by gut KdGag197–205-specific CD8
+ T cells were evaluated, although no IFN-γ, IL-2, IL-4,
IL-13 and IL-17 mRNA were detected, majority of the pools of hundred gut KdGag197–205-spe-
cific CD8+ T cells obtained from the three immunization regimes (i.n./i.n.- 9 out of 9; i.n./i.m.
and i.m./i.m.- 8 out of 10, i.e. 80–100%) expressed TNF-α, and the expression profile between
the three regimes were very similar (Fig 1a).
When chemokines MIP-1α, MIP-1β and RANTES mRNA expression profiles were evaluat-
ed, data indicated that although the level of MIP-1αmRNA expression was similar between
the three regimes, the number of hundred gut KdGag197–205-specific CD8
+ T pools expressing
MIP-1α were higher in the i.n./i.m and i.m./i.m. regimes compared to the purely mucosal i.n./
i.n. prime-booster regime (Fig 1b). Data also revealed that all cell pools (i.n./i.n.- 9/9, i.n./i.m
and i.m./i.m.-10/10) expressed MIP-1β and RANTES mRNA and the expression level of MIP-
1βmRNA was significantly higher in the i.n./i.m and i.m./i.m. groups and the RANTES mRNA
in the i.m./i.m. group compared to the i.n./i.n. group (MIP-1β i.n./i.n. vs. i.n./i.m. p = 0.045 and
Fig 1. Evaluation of TNF-α, chemokines and chemokine receptor mRNA expression in gut KdGag197–205–specific CD8
+ T cells following i.n./i.n., i.
n./i.m. and i.m./i.m. vaccination. BALB/c mice (n = 4–5 per group) were primed i.n. or i.m. with FPV-HIV and boosted i.n. or i.m. with VV-HIV, fourteen days
post boost immunization Peyer’s patches were pooled from all animals and cells were then stained with KdGag197–205 tetramer. These gut K
dGag197–205
—specific CD8
+ T cells were sorted in hundred cell pools (i.n./i.n. n = 9, i.n./i.m. n = 10 and i.m./i.m. n = 10 hundred cell pools) in a 96-wells plate, cDNA was
synthesized and mRNA expression profiles were evaluated using Fluidigm 48.48 dynamic arrays as described in methods. The log mRNA expression
normalised to housekeeping gene L32 (2-ΔCT, where ΔCT = CTgene—CTL32) of TNF-α (a), MIP-1α (b), MIP-1β (c), RANTES (d), CCR5 (e) is shown. All
chemokines tested and CCR5 expression in gut KdGag197–205-specific CD8
+ T cells following i.n./i.n. (blue), i.n./i.m. (red) and i.m./i.m.(green) vaccination is
summarized (f). In each plot (a-e), black circles indicate a pool of hundred gut KdGag197–205-specific CD8
+ T cells and black line indicate mean expression.
The experiment was repeated three times. Data represent the three experiments.
doi:10.1371/journal.pone.0126487.g001
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i.n./i.n. vs. i.m./i.m. p = 0.025; RANTES i.n./i.n. vs i.m./i.m. p = 0.0001) (Fig 1c and 1d). The
level of CCR5 mRNA expression by these gut KdGag197–205-specific CD8
+ cells were also found
to be similar to that of MIP-1β where i.n./i.n. vs. i.n./i.m and i.n./i.n. vs i.m./i.m. were signifi-
cantly elevated p = 0.003 (Fig 1e). In all three immunization regimes tested, the hierarchy of
these chemokine and/or their receptor mRNA expression by gut-KdGag197–205-specific CD8
+ T
cells was found to be RANTES>MIP-1β> CCR5>MIP-1α (Fig 1f).
When the levels of granzymes (A,B and C) and perforin mRNA expression by gut-
KdGag197–205-specific CD8
+ T cells were compared, in all three immunization regimes major
proportion of the hundred cell pools were found to express granzyme A and B mRNAs (60–
90%) but no granzyme C expression was detected in any of the immunization regimes tested.
Also, the levels of granzyme A and B mRNA expression were found to be similar between the
three immunization regimes tested (Fig 2a and 2b). In contrast, the number of perforin ex-
pressing gut-KdGag197–205-specific CD8
+ T cell pools were lower (40–60%), and the level of
perforin expression was significantly higher in the i.n./i.m and i.m./i.m. regimes compared to
i.n./i.n. strategy (i.n./i.n. vs. i.n./i.m. p = 0.035 and i.n./i.n. vs. i.m./i.m. p = 0.043) (Fig 2c).
Furthermore, when the expression of CD62L (also represented as ‘sell’), CD69, CCR7, CCR9,
CCR10 and P-selectin ligand (selplg) mRNA by gut-KdGag197–205-specific CD8
+ T cells were eval-
uated between the three immunization regimes, no expression of CD62L, CCR9 and CCR10 were
detected. However, compared to CCR7, lower numbers of gut-KdGag197–205-specific CD8
+ T cell
pools were found to be positive for P-selectin ligand and CD69 and no significant differences in
Fig 2. Evaluation of granzymes, perforin and receptor mRNA expression in gut KdGag197–205–specific CD8
+ T cells following i.n./i.n., i.n./i.m. and i.
m./i.m. vaccination.mRNA expression profile in i.n./i.n., i.n./i.m. and i.m./i.m. immunized pools of hundred gut KdGag197–205-specific CD8
+ T cells (i.n./i.n.
n = 9, i.n./i.m. n = 10 and i.m./i.m. n = 10 pools) were evaluated using Fluidigm 48.48 dynamic arrays as described in methods. The log mRNA expression
normalised to housekeeping gene L32 (2-ΔCT) of granzyme-A (a), granzyme-B (b), perforin (c), selplg or P-selctin ligand (d), CD69 (e) and CCR9 (f) is shown.
In each plot (a-f), black circles indicate a pool of hundred gut KdGag197–205-specific CD8
+ T cells and black line indicate mean expression. The experiment
was repeated three times. Data represent the three experiments.
doi:10.1371/journal.pone.0126487.g002
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the expression levels of these mRNA were detected between three immunization regimes tested
(Fig 2d–2f).
Different routes of vaccine delivery can induce distinct integrin mRNA
expression profiles in gut- KdGag197–205-specific CD8
+ T cells
It is established that α4 can heterodimerize with either β7 or β1 while αE can only heterodimerize
with β7. In the three immunization regimes tested, all the pools of hundred gut-KdGag197–205-
specific CD8+ T cells (100%) were found to express integrin α4, and the expression was signifi-
cantly higher in i.n./i.m. and i.m./i.m. compared to the purely mucosal i.n./i.n. immunization re-
gime (i.n./i.n. vs. i.n./i.m. and i.n./i.n. vs. i.m./i.m. p = 0.003) (Fig 3a). Data revealed that 100% of
gut-KdGag197–205-specific CD8
+ T cells were also positive for integrins β1 and β7 mRNA in all
the groups tested (Fig 3b & 3e). The expression level hierarchy of β1 mRNA was i.n./i.m> i.m./
i.m.> i.n./i.n. whereas expression level of β7 mRNA was similar in all the groups (Fig 3b & 3e).
Interestingly, when the α4, β1 and β7 mRNA expression by gut-KdGag197–205-specific CD8
+ T
cells were compared between the three immunization regimes (Fig 3c), α4 and β7 expression
profiles were found to be relatively higher and closely linked specifically in i.n./i.n. and i.n./i.m.
groups compared to the mean expression level of α4 and β1 mRNAs in all the groups (Fig 3c).
Although the levels of integrin αE (which can also pair with β7 integrin) mRNA expression
were similar between the three immunization regimes, 90–100% (i.n./i.n- 9/9, i.n./i.m.- 9/10) of
the pools of hundred gut-KdGag197–205-specific CD8
+ T cell obtained from i.n./i.n. and i.n./i.m
Fig 3. Evaluation of integrins α4, αE, β1 and β7 mRNA expression in gut KdGag197–205-specific CD8
+ T
cells following i.n./i.n., i.n./i.m. and i.m./i.m. vaccination. Integrins mRNA expression profile in i.n./i.n., i.n./
i.m. and i.m./i.m. immunized pools of hundred gut KdGag197–205-specific CD8
+ T cells (i.n./i.n. n = 9, i.n./i.m.
n = 10 and i.m./i.m. n = 10 pools) were evaluated using Fluidigm 48.48 dynamic arrays as described in
methods. The log mRNA expression normalised to housekeeping gene L32 of integrin α4 (a), β1 (b), α4
(black circle) which can pair up with β1 (red triangle) and β7 (green square) (c), αE (d), β7 (e) and αE (black
circle) which can pair up with β7 (green square) (f) is shown. The p values were calculated using one-way
ANOVA. In all the plots circles or triangles or square indicate a pool of hundred gut KdGag197–205-specific
CD8+ T cells and line indicate mean expression. The experiment was repeated three times. Data represent
the three experiments.
doi:10.1371/journal.pone.0126487.g003
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regimes (mucosally prime groups) expressed integrin αE compared to the purely systemic im-
munization strategy (only 3/10 or 30% of hundred cell pools expressed αE) (Fig 3d). Next when
the αE and β7 mRNA expression by gut-KdGag197–205-specific CD8
+ T cells were compared be-
tween the three immunization regimes, αE and β7 expression profiles were found to be more
closely associated in the i.n./i.n. purely mucosal vaccinated group compared to the i.n./i.m com-
bined mucosal systemic or i.m./i.m. purely systemic vaccinated groups (Fig 3f).
Furthermore, integrins αL, αM, αX and αD which can heterodimerize with β2 integrin were
evaluated in the three immunization regimes. Very low proportion of cell pools (1/10) were
found to express integrin αL in i.n./i.m. group compared to the purely mucosal and purely sys-
temic immunization groups, also the expression levels were not significantly different between
the three groups tested (Fig 4a). Data indicated that higher numbers of hundred cell pools ex-
pressed integrin αMmRNA in i.n./i.m. group (~50%) and i.m./i.m. group (~30%) compared to
i.n./i.n. group (~10%) (Fig 4b). Also, the expression was significantly higher in i.n./i.m and i.m./
i.m. compared to purely mucosal i.n./i.n. regime (Fig 4b). Major proportion of the hundred cell
pools (60%) obtained from i.n/i.m. group were found to express integrin αX, and the expression
levels were also found to be relatively higher in this group compared to purely mucosal and
purely systemic immunization regimes (Fig 4c). Unlike the expression pattern of integrins αM
and αX positive gut-KdGag197–205-specific CD8
+ T cells where the expression profile hierarchy
was i.n./i.m.> i.m./i.m.> i.n./i.n., higher proportions (80%) of gut-KdGag197–205-specific CD8
+
T cells expressed integrin αDmRNA in purely mucosal i.n./i.n. regime compared to i.n./i.m.
(10%) and i.m./i.m. (20%) groups (Fig 4d). Interestingly, in all the immunization regimes tested,
90–100% of gut-KdGag197–205-specific CD8
+ T cells were found to express integrin β2 and also
the expression levels were similar between the groups (Fig 4e). Next the integrin αD and β2
mRNA expression by gut-KdGag197–205-specific CD8
+ T cells were compared between the three
immunization regimes (Fig 4f). Based on 80% of cells in the i.n./i.n. group expressing integrin
αD and 100% of cells also expressing integrin β2, data suggest that integrin αD and β2 could be
Fig 4. Evaluation of integrins αL, αM, αX, αD and β2 mRNA expression in gut KdGag197–205–specific
CD8+ T cells following i.n./i.n., i.n./i.m. and i.m./i.m. vaccination. The log mRNA expression normalised to
housekeeping gene L32 of integrin αL (a), αM (b), αX (c), αD (d), β2 (e) αD (black circle) and β2 (inverted red
triangle) (f) and αX (green circle), αM (black circle) which can pair up with β2 (inverted red triangle) (g) is
shown. The p values were calculated using one-way ANOVA. In all the plots circles or triangles or square
indicate a pool of hundred gut KdGag197–205-specific CD8
+ T cells and line indicate mean expression. The
experiment was repeated three times. Data represent the three experiments.
doi:10.1371/journal.pone.0126487.g004
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more closely associated with i.n. delivery compared to i.m. delivery (Fig 4f). Similarly, when
integrin αM, αX and β2 were compared between the three groups (Fig 4g), in i.n./i.m. and i.m./i.
m. groups the integrins αM and β2 were found to be relatively higher and closely associated
compared to integrins αX and β2 (Fig 4g).
WT BALB/c and IL-13 KOmice have distinct mRNA expression profiles
in systemic and mucosal KdGag197–205-specific CD8
+ T cells
We have shown that i.n. FPV-HIV/ i.m. VV-HIV immunization strategy can induce robust and
sustained high avidity systemic and mucosal CD8+ T cell responses [10]. Thus, in this part of
the study, WT BALB/c and IL-13 KOmice (n = 4–5) were immunized i.n. FPV-HIV/ i.m.
VV-HIV strategy, 14 days post booster vaccination, gut and splenic KdGag197–205-specific CD8
+
T cell were sorted in groups of hundred cells, and mRNA expression profiles of the above same
30 genes were evaluated using Fluidigm 48.48 Dynamic arrays (Table 1). Interestingly, no IL-2,
IL-4, IL-13, IL-17 mRNA expression were detected in gut and splenic KdGag197–205-specific
CD8+ T cells in all mice groups tested. IFN-γ were detected in 40–50% of the hundred cell pools
obtained from spleen (WT BALB/c - 3/6, IL-13 KO - 2/5) and Peyer’s patch (WT BALB/c - 2/6,
IL-13 KO - 4/9) and the IFN-γmRNA expression level was relatively higher in splenic
KdGag197–205-specific CD8
+ T cells (WT spleen vs. Peyer’s patch p = 0.019) compared to Peyer’s
patches (Fig 5a). Unlike IFN-γmRNA expression, much greater proportion of cells were found
to express TNF-α (WT BALB/c spleen - 6/6, Peyer’s patch - 5/6; and IL-13 KO spleen - 5/5,
Peyer’s patch - 7/9), but no difference in the expression profiles were detected between gut and
splenic KdGag197–205-specific CD8
+ T cells obtained from the two mice groups (Fig 5b).
When chemokines MIP-1α, MIP-1β and RANTES mRNA expression inWT and IL-13 KO
gut and splenic KdGag197–205-specific CD8
+ T cells were evaluated, compared to MIP-1β and
RANTES relatively lower numbers of gut and splenic-KdGag197–205-specific CD8
+ T cell pools ex-
pressed MIP-1αmRNA (WT BALB/c spleen - 5/6, Peyer’s patch - 4/6; and IL-13 KO spleen - 4/5,
Peyer’s patch - 5/9) (Fig 6a). In bothWT and IL-13 KO groups, the expression levels of MIP-1α
Fig 5. Evaluation of cytokine mRNA expression in WT BALB/c and IL-13 KO gut and splenic
KdGag197–205-specific CD8
+ T cells following i.n./i.m. vaccination.WT BALB/c and IL-13 KOmice
(n = 4–5/ group) were prime-boost immunized with i.n. FPV-HIV/ i.m. VV-HIV. Fourteen days post booster
vaccination mRNA expression profiles in gut and splenic KdGag197–205-specific CD8
+ T cells were evaluated
using Fluidigm 48.48 dynamic arrays as described in methods. WT BALB/c spleen (SP) and Peyer’s patch
(PP) n = 6 pools of hundred KdGag197–205-specific CD8
+ T cells are indicated by blue circle and triangle
respectively. IL-13 KOmice spleen n = 5 and Peyer’s patch n = 9 pools of hundred KdGag197–205-specific
CD8+ T cells are indicated by red circles and triangles respectively. Data indicate log mRNA expression of
IFN-γ (a) and TNF-α (b) normalised to housekeeping gene L32. The experiment was repeated three times.
Data represent the three experiments.
doi:10.1371/journal.pone.0126487.g005
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were significantly elevated in splenic KdGag197–205-specific CD8
+ T cells compared to Peyer’s
patches (spleen vs. Peyer’s patch p = 0.044 and 0.003 respectively) (Fig 6a). Similarly, in all the
groups tested even though 100% of KdGag197–205-specific CD8
+ T cells were positive for MIP-1β
and RANTES, the expression levels were significantly higher in spleen compared to Peyer’s patch
(MIP-1β expression inWT and IL-13KO, spleen vs. Peyer’s patch p = 0.001 and 0.007 respectively;
RANTES inWT group spleen vs. Peyer’s patch p = 0.004) (Fig 6b & 6c). Interestingly, in these
groups the level of CCR5mRNA expression between gut and splenic KdGag197–205-specific CD8
+
T cells were very similar, and compared to RANTES andMIP1- β, the proportion of cells express-
ing CCR5 were relatively lower (WT BALB/c spleen - 5/6, Peyer’s patch - 4/6; and IL-13 KO
spleen - 3/5, Peyer’s patch - 8/9) (Fig 6d). InWT BALB/c or IL-13 KO group the hierarchy of che-
mokine and/or their receptor mRNA expression by gut and splenic KdGag197–205-specific CD8
+ T
cells was found to be RANTES>MIP-1β>MIP-1α CCR5 (Fig 6e).
When the expression of granzyme A, B and C mRNA in WT and IL-13 KO gut and splenic
KdGag197–205-specific CD8
+ T cells were evaluated, major proportion of the hundred cell pools
were found to express granzyme A and B mRNAs (80–100%) (Fig 7a & 7b) but no granzyme
C expression was detected in any of the groups tested. Although the expression levels of gran-
zyme A and B were found to be similar in WT and IL-13 KO splenic and gut KdGag197–205-
specific CD8+ T cells (Fig 7a & 7b) 100% (9/9) of the IL-13 KO gut-specific cell pools expressed
B. Interestingly, in both compartments in WT and IL-13 KO groups 80–100% of hundred cell
pools were positive for perforin, but expression levels were relatively higher in spleen compared
Fig 6. Evaluation of chemokines and chemokine receptor mRNA expression in WT BALB/c and IL-13
KO gut and splenic KdGag197–205-specific CD8
+ T cells following i.n./i.m. vaccination. Exactly as in fig
5 WT BALB/c and IL-13 KOmice (n = 4–5/ group) were prime-boost immunized with i.n. FPV-HIV/ i.m.
VV-HIV. and mRNA expression profiles in gut and splenic KdGag197–205-specific CD8
+ T cells were
evaluated. WT BALB/c spleen (SP) and Peyer’s patch (PP) n = 6 pools of hundred KdGag197–205-specific
CD8+ T cells are indicated by blue circle and triangle respectively. IL-13 KOmice spleen n = 5 and Peyer’s
patch n = 9 pools of hundred KdGag197–205-specific CD8
+ T cells are indicated by red circles and triangles
respectively. Data indicate log mRNA expression of MIP-1α (a) MIP-1β (b) and RANTES (c) CCR5 (d)
normalised to housekeeping gene L32. Fig 6e indicates the summary of chemokine and CCR5 data.
doi:10.1371/journal.pone.0126487.g006
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to Peyer’s patch (Fig 7c). Furthermore, in WT and IL-13 KO groups, similar proportions of
cells were found to express P-selectin ligand and CD69 mRNA in both compartments (WT
BALB/c spleen- 4 to 5/6, Peyer’s patch- 4 to 6/6; and IL-13 KO spleen- 3 to 4/5, Peyer’s patch-
7 to 8/9), and their expression levels were also very similar (Fig 7d & 7e).
Interestingly, when the memory markers CD62L and CCR7mRNA expression was evaluated
in all the groups, the CD62L mRNA expression was only detected in gut KdGag197–205-specific
CD8+ (WT BALB/c 5/6 and IL-13 KO 4/9) whereas CCR7 mRNA expression was detected in
both splenic and gut KdGag197–205-specific CD8
+ T cells (WT BALB/c spleen- 4/6, Peyer’s
patch- 5/6; and IL-13 KO spleen- 2/5, Peyer’s patch- 5/9) (Fig 7f). The expression levels of
CCR7 mRNA were found to be similar in the two compartments (Fig 7f). However, CD62L and
CCR7 were found to be closely associated in Peyer’s Patch samples compared to spleen (Fig 7f).
WT and IL-13 KOmice have distinct integrins and CCR9 mRNA
expression profiles in gut and splenic KdGag197–205-specific CD8
+ T
cells
Integrins α4, αE, β1, β7 and CCR9 expression were evaluated inWT BALB/c and IL-13 KOmice
gut and splenic KdGag197–205-specific CD8
+ T cells. Data revealed that all gut and splenic cells ex-
pressed integrin α4 mRNA and expression levels were relatively higher in spleen compared to
Peyer’s patches, specifically in IL-13 KOmice where spleen vs. Peyer’s patch p = 0.033 (Fig 8a).
In contrast, in both the groups tested, majority of hundred cell pools that expressed integrin αE
were detected in Peyer’s patch (WT BALB/c ~80%, IL-13 KO ~55%) but not in spleen and ex-
pression levels were also found to be elevated in gut-KdGag197–205-specific CD8
+ T cells (Fig 8b).
Data also revealed all the cell pools expressed integrins β1 and β7 mRNAs and their expression
levels were significantly higher inWT BALB/c and IL-13 KO splenic KdGag197–205-specific CD8
+
T cells (inWT BALB/c and IL-13 KO groups, β1 expression, spleen vs. Peyer’s patch p = 0.001;
β7 expression, spleen vs. Peyer’s patch p = 0.01) (Fig 8c & 8d). Furthermore, when the CCR9 and
Fig 7. Evaluation of granzymes, perforin and receptor mRNA expression in WT BALB/c and IL-13 KO
gut and splenic KdGag197–205-specific CD8
+ T cells following i.n./i.m. vaccination.mRNA expression
profiles in WT BALB/c and IL-13KO gut and splenic KdGag197–205-specific CD8
+ T cells were evaluated using
Fluidigm 48.48 dynamic arrays as described in methods. WT BALB/c spleen (SP) and Peyer’s patch (PP)
n = 6 pools of hundred KdGag197–205-specific CD8
+ T cells are indicated by blue circle and triangle
respectively. IL-13 KOmice spleen n = 5 and Peyer’s patch n = 9 pools of hundred KdGag197–205-specific
CD8+ T cells are indicated by red circles and triangles respectively. Data indicate log mRNA expression of
granzyme A (a) granzyme B (b) perforin (c) selplg or P-selectin ligand (d) CD69 (e) and memory markers sell
(CD62L) and CCR7 (f) normalised to housekeeping gene L32. The experiment was repeated three times.
Data represent the three experiments.
doi:10.1371/journal.pone.0126487.g007
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CCR10 mRNA expression were evaluated, very low numbers of gut- KdGag197–205-specific CD8
+
T cells (WT BALB/c, spleen 0/6 and Peyer’s patch 1/6; in IL-13KO spleen 1/5 and Peyer’s patch
3/9) were found to express CCR9 (Fig 8e) and no CCR10 mRNA expression was detected.
Furthermore, when the expression of integrin αL, αM, αX and αDmRNAs which are
known to heterodimerize with integrin β2 were evaluated in both the groups, no integrin αD
expression was detected. Lower proportion of gut/splenic KdGag197–205-specific CD8
+ T cells
(20–30%) were found to express integrin αL and expression levels were similar in both the
compartments and the two groups (Fig 9a). In contrast, higher numbers of WT BALB/c and
IL-13 KO mice splenic KdGag197–205-specific CD8
+ T cell pools were positive for integrin αM
compared to Peyer’s patch (WT BALB/c group, spleen 6/6 and Peyer’s patch 1/6; IL-13 KO
group, spleen 1/5 and Peyer’s patch 4/9) and also the expression level was relatively elevated in
splenic KdGag197–205-specific CD8
+ T cells (Fig 9b). Likewise, in all the groups tested, although
the proportions of cell pools positive for integrin αX were found to be similar, expression level
was higher in splenic KdGag197–205-specific CD8
+ T cells compared to Peyer’s patches (Fig 9c).
Interestingly, most or all cell pools expressed obtained from both mice groups expressed integ-
rin β2, and expression levels were relatively higher in splenic KdGag197–205-specific CD8
+ T
cells compared to Peyer’s patch (Fig 9d).
IL-13 KOmice have elevated α4β7+ and CCR9+ gut KdGag197–205-
specific CD8+ T cells
WTBALB/c and IL-13 KOmice were prime boost immunized using i.n. FPV-HIV/i.m. VV-HIV
strategy. Fourteen days post booster vaccination, splenic and gut KdGag197–205-specific CD8
+ T cell
Fig 8. Evaluation of integrins α4, αE, β1and β7 and CCR9mRNA expression in WT BALB/c and IL-13
KO gut and splenic KdGag197–205-specific CD8
+ T cells following i.n./i.m. vaccination.mRNA
expression profiles in WT BALB/c and IL-13KO gut and splenic KdGag197–205-specific CD8
+ T cells were
evaluated using Fluidigm 48.48 dynamic arrays as described in methods. WT BALB/c spleen (SP) and
Peyer’s patch (PP) n = 6 pools of hundred KdGag197–205-specific CD8
+ T cells are indicated by blue circle and
triangle respectively. IL-13 KOmice spleen n = 5 and Peyer’s patch n = 9 pools of hundred KdGag197–
205-specific CD8
+ T cells are indicated by red circles and triangles respectively. Data indicate log mRNA
expression of integrin α4 (a) αE (b) β1 (c) β7 (d) and CCR9 (e) normalised to housekeeping gene L32. The
experiment was repeated three times. Data represent the three experiments.
doi:10.1371/journal.pone.0126487.g008
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responses were evaluated using KdGag197–205-tetramer staining together with α4β7 and CCR9
staining using FACS analysis. Data revealed that the magnitude of KdGag197–205-specific splenic
CD8+ T cell numbers were similar between the two mice groups tested (Fig 10), which was consis-
tent to our previous findings [12]. Notably, the percentages of α4β7+ splenic KdGag197–205-specfic
CD8+ T cells were much elevated inWT and IL-13 KOmice compared to CCR9 (α4β7+ ~1.5%
and CCR9 less than 0.5%, p< 0.0001 (Fig 10b & 10c), but, no significant difference in expression
was detected betweenWT BALB/c and IL-13 KO splenic groups (Fig 10b & 10c). In contrast, com-
pared toWTmice the percentages of α4β7+ and CCR9+ gut-KdGag197–205-specfic CD8
+ T cells
were found to be significantly elevated in IL-13 KOmice compared to theWT BALB/c (Fig 10e &
10f). When the frequency of α4β7 and CCR9 were assessed in spleen vs. gut KdGag197–205-specific
CD8+ T cells obtained fromWT and IL-13 KO groups, threefold increase in the expression fre-
quency of α4β7 and CCR9 were detected in Peyer’s patches (~ 60%) compared to spleen (~ 20%)
(Fig 10g & 10h).
Discussion
Studies have shown that mucosal immune responses are most efficiently induced by administra-
tion of vaccines to the mucosae, whereas systemic immunization strategies rarely induce long
lasting or optimal mucosal immunity and are therefore less effective against infection at the mu-
cosal surfaces [25, 26]. The Sabin live attenuated oral polio vaccine (OPV) introduced in 1950s is
a classic example of an effective mucosal vaccine. Unlike the injectable inactivated polio vaccine
(IPV), OPV was shown to induce secretory IgA antibody responses at the intestinal mucosae the
Fig 9. Evaluation of integrins αL, αM, αX and β2 mRNA expression in WT BALB/c and IL-13 KO gut
and splenic KdGag197–205–specific CD8
+ T cells following i.n./i.m. vaccination. Exactly as in Fig 8,
mRNA expression profiles in WT BALB/c and IL-13KO gut and splenic KdGag197–205-specific CD8
+ T cells
were evaluated. WT BALB/c spleen (SP) and Peyer’s patch (PP) n = 6 pools of hundred KdGag197–205–
specific CD8+ T cells are indicated in blue circles and triangles respectively. IL-13 KOmice spleen n = 5 and
Peyer’s patch n = 9 pools of hundred KdGag197–205-specific CD8
+ T cells are indicated by red circles and
triangles respectively. Data indicate log mRNA expression of integrin αL (a) αM (b) αX (c) and β2 (d)
normalised to housekeeping gene L32.
doi:10.1371/journal.pone.0126487.g009
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site of virus replication helping effective control of poliovirus, making OPV a powerful strategy
for global eradication of polio [27]. We have shown that i) vaccine regime (i.e. systemic vs. mu-
cosal delivery) can significantly influence the magnitude as well as the quality/avidity of immune
response at the mucosae [9, 10] and ii), mucosal verses systemic immunization regimes can in-
duce distinct gene expression profiles in splenic KdGag197–205-specific single CD8
+ T cells [10].
In the current study evaluating the expression of thirty different genes in gut-KdGag197–205-spe-
cific CD8+ T cells using Fluidigm 48.48 dynamic arrays have further established that different
vaccine delivery routes can vastly influence the gene expression profiles in mucosal and systemic
compartments. Specifically, compared to purely mucosal (i.n./i.n.) FPV-HIV/VV-HIV prime-
boost immunization regime, combined systemic mucosal (i.n./i.m.) and purely systemic (i.m./
i.m.) immunization regimes showed enhanced expression of MIP-1β, RANTES, and CCR5
mRNAs in gut KdGag197–205-specific CD8
+ T cells indicating that enhanced expression of these
chemokines/chemokine receptor genes were most likely driven by the systemic antigen en-
counter following the i.m. VV-HIV booster vaccination. Our antibody array studies have also
revealed enhanced expression of RANTES by HIV-specific CD8+ splenocytes following i.n.
FPV-HIV/ i.m. VV-HIV immunization compared to i.m. pDNA-HIV/ i.n. FPV-HIV vaccina-
tion [6]. Furthermore, compared toWT BALB/c mice, IL-13 KOmice immunized with i.n.
FPV-HIV/ i.m. VV-HIV vaccination strategy has also shown to induce higher avidity CD8+ T
cells with better protective efficacy [12] and this was associated with significantly enhanced
RANTES mRNA expression by splenic KdGag197–205-specific single memory CD8
+ T cells [12].
These studies also indicated that in antigen-specific CD8+ T cells, RANTES is regulated by IL-4
Fig 10. Evaluation of WT BALB/c and IL-13 KO gut and splenic KdGag197–205 –specific CD8
+ α4β7+ and KdGag197–205 –specific CD8
+ CCR9+ T cells
following i.n./i.m. vaccination.WT BALB/c and IL-13 KOmice were prime boost immunized using i.n. FPV-HIV/i.m. VV-HIV strategy. Fourteen days post
booster vaccination, splenic and gut KdGag197–205-specific CD8
+ T cell responses were evaluated using KdGag197–205-tetramer staining together with α4β7
and CCR9 staining using FACS analysis. The percentage of WT BALB/c (blue) and IL-13 KO (red) splenic and gut KdGag197–205-tetramer
+ CD8+ T cells (a
and d), KdGag197–205-tetramer
+ CD8+ α4β7+ T cells (b and e), KdGag197–205-tetramer
+ CD8+ CCR9+ T cells (c and f) is shown. The percentage frequency of
α4β7 and CCR9 homing marker expression onWT BALB/c and IL-13 KO splenic (g) and gut (h) KdGag197–205-tetramer
+ CD8+ T cells is also shown. Data
represent 4–5 experiments.
doi:10.1371/journal.pone.0126487.g010
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and lL-13 [12]. The current data further substantiated these findings as absence of IL-13 corre-
lated with higher expression of RANTES and MIP-1β in splenic KdGag197–205-specific CD8
+
T cells.
In previous single cell profiling studies, majority of splenic KdGag197–205-specific single
(~80%) CD8+ T cells were found to express IFN-γ and lower proportion was found to ex-
press TNF-α (1–5%) [10]. However, in this study no IFN-γ expression was detected in the
gut KdGag197–205-specific CD8
+ T cells. In contrast, in all three immunization regimes test-
ed, 80–90% of the gut KdGag197–205-specific CD8
+ T cells were found to be positive for
TNF-α. Interestingly, TNF-α have been associated with increased migration and prolifera-
tion of intraepithelial lymphocytes in gut [28] and this may explain the differences observed
in CD8+ T cell cytokine specificities in spleen and gut compartments [6, 10]. Furthermore,
the discrepancy in IFN-γ expression profile, compared to the previous studies [10] could
also be due evaluating mRNA from 100 KdGag197–205-specific CD8
+ T cells not single cell
level using Fluidigm 48.48 dynamic array analysis which could be a major caveat. Specifical-
ly, it is likely that in a pool of hundred cells the abundance of an mRNA like IFN-γ could be
extremely high and this has high potential to inhibit optimum PCR amplification of these
genes [29] [Note that in this study 30 genes were amplified from a single cDNA sample ob-
tained from 100 cells and the abundance of the 30 gene transcripts will be vastly different
(for example; elevated IFN-γ vs lower levels of integrin αD mRNA). Thus, in an ideal sce-
nario the most abundant genes will have to be diluted to obtain the optimum amplification
outcomes [29]].
Surprisingly, following i.n./i.m immunization no significant differences between the control
WT BALB/c and IL-13 KO gut KdGag197–205-specific CD8
+ T cells were detected at a 100-cell
level. However, previous studies in our laboratory have reported greatly elevated expression of
granzyme B in IL-13 KO splenic KdGag197–205-specific single CD8
+ T cells compared to other
groups tested [12]. Similarly, when mRNA expression profiles were evaluated at a single cell
level enhanced expression of RANTES, MIP-1β, perforin and also granzymes A and B by gut
KdGag197–205-specific CD8
+ T cells were detected in IL-13 KO mice compared to WT BALB/c
mice (Trivedi et. al., manuscript submitted). Several other recent studies also have illustrated
the power and necessity of using single-cell gene expression profiling approaches in evaluating
vaccine efficacy or immune outcomes following infection [30–32]. For example, recent study
by Flatz et. al., have shown qualitative differences between CD8+ T cell responses following dif-
ferent prime-boost immunization strategies (DNA/rAd5, rAd5/rAd5 and rAd5/rLCMV) when
data were analysed at a single-cell gene expression level compared to pooled analysis [31]. Cur-
rent data taken together with our single-cell gene expression data (Trivedi et. al., manuscript
submitted) clearly reveal that when evaluating the outcome of an immune response, single cell
gene expression profiling has high potential to generate more powerful information than
pooled cell analysis.
Current study indicated that according to the anatomical location in which the KdGag197–
205-specific CD8
+ T cells were obtained (spleen vs Peyer’s patch) the mRNA expression profiles
were significantly different both in WT BALB/c and IL-13 KO mice. This is consistent with
studies by Masopust et. al. [13] where they showed that anatomical location played an impor-
tant role in modulating memory T cell immunity. Specifically, unlike Peyer’s patches, splenic
KdGag197–205-specific CD8
+ T cells expressed CCR7 but lacked CD62L suggesting that tissue
microenvironment regulated memory cell surface marker expression and memory T cell differ-
entiation. Rapid down-regulation of CD62L by splenic KdGag197–205-specific CD8
+ T cells has
often been correlated with the loss of T cell trafficking to peripheral lymph nodes [33]. Accord-
ing to the current findings it appears that gut KdGag197–205-specific CD8
+ T cells most likely re-
tain CD62L expression which enable them to rapidly reenter lymph nodes [34, 35].
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This study was one of the first to evaluate an array of integrins that are reported to be pres-
ent on lymphocytes and their expression profile following different routes of vaccination and
conditions. Several studies have now shown that integrins like α4β7 is differentially expressed
on T cells and they play a role in tissue-specific T cell homing in an immunization route depen-
dent manner [22, 24, 36–38]. Interestingly, current study clearly demonstrated that in a prime-
boost vaccination setting, the prime or the booster immunization could differentially influence
the integrin expression profile on gut KdGag197–205-specific CD8
+ T cells. For example; elevated
numbers of integrin αE expressing KdGag197–205-specific CD8
+ T cells were detected in gut fol-
lowing mucosal but not systemic priming, indicating that the mucosal micro-environment was
responsible for altering the αE homing marker expression. This is consistent with another find-
ing where integrin β7 was also found to be up-regulated on T cells primed in mesenteric lymph
nodes which home to the mucosae [37]. Integrin αE normally pairs up with β7 and is known
to facilitate retention of lymphocytes in the gut via interaction with E-cadherin [39, 40]. In this
study αE and β7 integrins were found to be more closely associated together in an i.n./i.n. vac-
cinated setting compared to the i.n./i.m or i.m./i.m. vaccinated groups. Recent studies have
shown that during mucosal T cell priming, dendritic cells play a critical role in imprinting
antigen-specific T cells with different homing markers and this is also retinoic acid dependent
[20, 41]. Moreover, integrins α4 and β7 were found to be more closely associated together in all
vaccinated groups tested compared to integrins α4 and β1. It is now well established that integ-
rin heterodimer α4β7 help T cell migration to the gut mucosae [20, 22]. In the current study,
following i.m. booster vaccination significantly enhanced integrin α4 mRNA expressing gut
KdGag197–205-specific effector CD8
+ T cells were detected. This suggested that i.m. booster vac-
cination may have high potential to promote the expansion of mucosally originated antigen-
specific CD8+ T cells (primed at the mucosae) in the systemic compartment. This hypothesis
can be further substantiate as, higher α4 and β7 mRNA were detected also in splenic KdGag197–
205-specific CD8
+ T cells suggesting that these cells may continue to circulate between the mu-
cosal and systemic compartments. However, the full dynamics involved in tissue environment
and the role of integrins in T cell homing is yet to be discovered.
Furthermore, following mucosal and systemic immunization all gut-KdGag197–205-specific
CD8+ T cells were found to express integrin β2. Studies have shown that integrin β2 (known
to heterodimerize with αL, αM, αX and αD) play a critical role in T cell activation and in trans-
endothelial migration [42, 43]. Unlike αL, αM, and αX, integrin β2 were found to be closely
associated with integrin αD in an i.n./i.n. setting compared to the other two strategies tested.
However, the function of integrin αD in a vaccination context has not yet been fully character-
ized. In contrast, the integrins αM and β2 were found to be relatively higher and closely associ-
ated in an i.n./i.m. and i.m./i.m. setting, further highlighting that immunization route/strategy
can significantly regulate the expression of integrins on T cells.
Interestingly, compared to WT control the number of gut KdGag197–205-specific CD8
+ T
cells expressing gut-homing markers α4β7 and CCR9 protein were found to be significantly
higher in IL-13 KO as well as IL-4 KO mice (unpublished observation in our laboratory).
New vaccines that transiently inhibited IL-4/IL-13 [44, 45] also enhanced integrin α4 mRNA
expression in gut KdGag197–205-specific single CD8
+ T cells (Trivedi et. al., manuscript sub-
mitted). These observations suggest that inhibition of IL-13 or IL-4, most likely help increase
trafficking of KdGag197–205-specific CD8
+ T cells to gut mucosae. Other studies also have
shown the role of cytokines such as IL-12, IL-4 and TGF-β in regulating tissue-specific lym-
phocyte trafficking [46–48]. We have established that transient inhibition of IL-4 and IL-13
can significantly modulate the antigen presenting cell subsets at the vaccination site and
induce a high avidity T cell repertoire [49]. Thus, we suggest that IL-4/ IL-13 depleted cell
milieu most likely help create an unique T cell subset with specific homing capacities to the
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mucosal sites. The exact mechanisms how IL-4 and/or IL-13 modulate T cell homing war-
rants further investigation.
Collectively, the current data indicated that out of the thirty genes tested, at the pooled 100
cell level, the MIP-1β, RANTES, CCR5, perforin and integrin α4 mRNA expression were sig-
nificantly different in the three immunization regimes tested. Similarly, the expression levels of
MIP-1α, MIP-1β, RANTES, integrins α4, β1 and β7 mRNAs were markedly different between
mucosal and systemic compartments. These observations further emphasize that the route of
vaccine delivery, tissue microenvironment plus the cytokine milieu (specifically IL-13) can sig-
nificantly influence the gene expression profiles of KdGag197–205-specific CD8
+ T cells and
modulate their functional specificities (high verses low avidity) as well as cell homing capabili-
ties. In conclusion, the above findings corroborate that these factors have to be seriously taken
into consideration when designing novel/effective vaccines strategies that can induce optimal
mucosal CD8+ T cell immunity against chronic pathogens such as HIV-1.
Materials and Methods
Immunization of mice
Pathogen-free 6 to 8 week old female WT BALB/c and IL-13 KO mice on BALB/c background
were purchased from the Australian Phenomics Facility, the Australian National University
(ANU). WT BALB/c mice were prime-boost immunized with 1 X 107 PFU rFPV followed by 1
X 107 PFU rVV expressing HIV-antigens, under isoflurane anesthesia 2 weeks apart using mu-
cosal and systemic routes of vaccination. IL-13 KO mice were prime-boost immunized with i.
n. rFPV/ i.m. rVV. The i.n. rFPV was given in a final volume of 20–25 μl, where i.m. rVV im-
munization was delivered in a 100 μl volume. All viruses were diluted in sterile phosphate-buff-
ered saline (PBS) and then sonicated, to obtain homogeneous viral suspensions before delivery.
Ethics Statement
All animals were maintained and experiments were performed in accordance with the Austra-
lian NHMRC guidelines within the Australian Code of Practice for the Care and Use of Ani-
mals for Scientific Purposes and in accordance with guidelines approved by the Australian
National University Animal Experimentation and Ethics Committee (AEEC). This study was
approved by the AEEC and listed under ANU ethics protocol number A2011/018. All animals
were anesthetized using isoflurane and monitored daily. At the end of the experiments were
ethically sacrificed using cervical dislocation in accordance with the above AEEC approved
protocols.
Mucosal and systemic lymphocytes preparation
The mice were euthanized using cervical dislocation, spleen and Peyer’s patches were removed
and single cell suspensions were prepared as described previously [45, 50]. Briefly, the spleen
cells were passed through a cell strainer and were treated with red blood cell lysis buffer for 7
min at room temperature, cells were then washed, and suspended in complete RPMI (RPMI sup-
plemented with 7% fetal calf serum, 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid,
30 μg ml− 1 penicillin, 50 μg ml− 1 streptomycin, 2 mM sodium pyruvate (Gibco-Invitrogen,
Auckland, NZ), and 50M 2-mercaptoethanol (Sigma, St Louis, MO), and kept at 4°C until use,
similarly Peyer’s patches were prepared without the red cell lysis step. The Peyer’s patch cells
were filtered through the small piece of gauze to remove debris prior to final suspension in com-
plete RPMI medium.
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Tetramer and homing marker staining
Allophycocyanin (APC) conjugated KdGag197–205 tetramers were synthesized at the Bio-
Molecular Resource Facility at The John Curtin School of Medical Research (BRF/JCSMR),
ANU. Tetramer staining was performed as described previously [9, 10]. Briefly, 2 X 106 spleno-
cytes and Peyer’s patches were stained with anti-CD8α FITC antibody and APC conjugated
KdGag197–205 tetramer at room temperature for 40 min. After washing cells twice with FACS
buffer (PBS with 1% fetal calf serum), the cell pellets were resuspended in 0.5% PFA (except for
studies involving cell sorting). For gene expression profile analysis, KdGag197–205-specific hun-
dred cells (from pooled splenocytes or Peyer’s patches) were sorted into 96-well plates using
stringent gating strategy as described previously [10] [40]. NOTE: The purpose of this study
was to assess the expression of these genes specifically in tetramer-specific CD8 T cells (with
no prior antigen stimulation) similar to our previous studies. It is well established that antigen-
activation (stimulation with specific-peptide) and tetramer staining cannot be performed con-
currently, as i) stimulation prior to tetramer binding can lead to loss of tetramer staining due
to down-regulation of the T-cell receptors and ii) peptide and tetramer competes for the same
binding site and this leads to a competition and reduce tetramer staining.
For homing markers analysis, first the cells were stained with APC-conjugated tetramer for
40 min and then were surface stained with biotin labelled anti-mouse LPAM-1 or α4β7 and
FITC conjugated anti-mouse CCR9 antibodies for 25 min at 4°C, followed by brilliant violet
421 streptavidin (useful for indirect staining of biotin labelled α4β7 primary antibody) for an-
other 25 min at 4°C. Cells were fixed and total 106 events per sample were collected using For-
tessa flow cytometer (Becton-Dickinson), and the results were analyzed using Cell Quest Pro
software. Note: frequency of homing marker expression out of the total KdGag197–205-tetramer
+
CD8+ T cell population was calculated as in Xi et. al. [50].
Evaluation of mRNA expression in hundred KdGag197–205-tetramer
+
CD8+ T cells
KdGag197–205 tetramer
+ CD8+ hundred cells from spleen and/ Peyer’s patches were sorted
using cell FACS Aria I (BD Biosciences) into 96-well plates containing CellsDirect qRT-PCR
reaction buffer (Invitrogen), Platinum Taq polymerase / SuperScript III reverse transcriptase
(Invitrogen), a mixture of Taqman primer-probes at 0.2X concentration specific for the tran-
scripts of interest, as listed in Table 1 (Applied Biosystems), and SuperaseIn RNase inhibitor.
Immediately following cell sorting, samples were centrifuged, and subjected to 20 cycles of pre
amplification using polymerase chain reaction (PCR) (cell cycling as: 1 X 50°C 15 min for the
reverse transcription then 1 X 95°C 2 min for reverse transcriptase inactivation and Taq poly-
merase activation, followed by 20 X 95°C 15 s and 60°C 4 min amplification cycle). Subse-
quently, the pre-amplified cDNA was stored at -20°C until analysis and was diluted with dH2O
(1:2) prior to qPCR reaction. Each pre-amplified cDNA sample was then separated into 48 sep-
arate reactions for qPCR analysis using the BioMark 48.48 dynamic array nanofluidic chip
(Fluidigm Inc., USA) according to manufacturer’s instruction.
Briefly, following hydraulic chip priming, 47 preamplified cDNA samples plus one no tem-
plate standard were mixed with a mild detergent loading solution to allow capillary flow, and
the samples were added to the sample inlets of 48.48 nanofluidic chip (Fluidigm, Inc.), 30 indi-
vidual Taqman primer-probe mixtures (Applied Biosystems) specific for individual transcripts
of interest listed in Table 1 along with assay loading solution were also added into the specific
assay inlets of the 48.48 nanofluidic chip, allowing a combination of each sample to mix with
each primer-probe assay in every possible combination (a total of 2304 reactions). The chip
was then thermo-cycled through 40 cycles and Taqman primer-probe fluorescence in the FAM
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channel was detected using the CCD (charge-coupled device) camera attached to the BioMark
HD system, normalized by ROX (6-carboxy-X-rhodamine) intensity. The statistical analyses of
the data were performed as described below.
Statistical analysis
Amplification signals were analysed and Ct values were determined using Fluidigm’s real-time
PCR analysis software version 4. The Ct values of genes were normalized against housekeeping
gene ribosomal protein L32 (ΔCt = Ctgene—CtL32), data represents the mRNA fold expression
relative to housekeeping gene (2-ΔCt). The error bars represents standard error of mean and the
p values were determined using one-way analysis of variance followed by Sidak multiple com-
parison test or Dunnett (2-sided) post tests using IBM SPSS version 21. For the flow-cytometer
analysis, the standard error of the mean and p values were determined using two-tailed Stu-
dent’s t-test, using GraphPad Prism software version 5. Raw Fluidigm’s real-time PCR data can
be found in supporting information (S1 and S2 Datasets).
Supporting Information
S1 Dataset. Ct values of genes expressed in gut HIV-specific CD8 T cells following different
routes of immunization.
(XLSX)
S2 Dataset. Ct values of genes expressed in systemic and mucosal HIV-specifi CD8 T cells
obtained fromWT and IL-13 KO mice.
(XLSX)
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